By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Immune Pharmaceuticals, Inc. 

150 Broadway
Suite 1801
New York  New York  10038  U.S.A.
Phone: 646-937-1941 Fax: n/a




Company News
Immune Pharma Signs Letter Of Intent With Pint Pharma Regarding License And Commercializion Of Ceplene In Latin America 4/20/2017 6:32:08 AM
Immune Pharma Announces 1-for-20 Reverse Stock Split 4/12/2017 10:10:15 AM
Immune Pharma Granted Additional Time To Comply With Nasdaq Listing Requirement 3/13/2017 10:46:27 AM
Immune Pharma Reports Encouraging Preliminary Data With Bertilimumab In An Open Label Phase II Study In The Rare Dermatological Auto-Immune Disease, Bullous Pemphigoid 2/28/2017 7:43:13 AM
Immune Pharma Announces The Launch Of REMAIN, An International Overall Survival Study With Ceplene And Low Dose Proleukin In Remission Maintenance In Acute Myeloid Leukemia 2/17/2017 7:40:19 AM
Immune Pharma Appoints New Chairman Of The Board Of Directors 1/27/2017 7:02:22 AM
Immune Pharma Enters A Research Partnership To Develop Mono- And Bispecific Antibodies Against Novel Targets In The Tumor Microenvironment 1/23/2017 9:59:04 AM
Immune Pharma Release: Company Will Request An Appeal To Regain Compliance With Nasdaq's Minimum Bid Price Rule 1/10/2017 6:47:10 AM
Immune Pharma Announces Immuno-Oncology R&D Update On December 8, 2016 11/22/2016 10:19:07 AM
Immune Pharma Secures Up To $11 Million In New Financing To Be Deployed With A Focus On Bertilimumab Clinical Development 11/17/2016 10:14:03 AM